Vaishali Sanchorawala

Summary

Affiliation: Boston University School of Medicine
Country: USA

Publications

  1. pmc Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial
    Vaishali Sanchorawala
    Amyloid Treatment and Research Program, Section of Hematology and Oncology, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA
    Haematologica 98:789-92. 2013
  2. ncbi request reprint AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes
    V Sanchorawala
    Department of Medicine, Boston University Medical Center, Boston, MA, USA
    Am J Hematol 81:692-5. 2006
  3. ncbi request reprint Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis
    V Sanchorawala
    Department of Medicine, Section of Hematology Oncology, Boston Medical Center, Boston, MA 02118, USA
    Bone Marrow Transplant 36:597-600. 2005
  4. ncbi request reprint Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
    Vaishali Sanchorawala
    Department of Medicine, F 302, 732 Harrison Ave, Boston University Medical Center, MA 02118, USA
    Blood 109:492-6. 2007
  5. ncbi request reprint High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial
    V Sanchorawala
    Hematology and Stem Cell Transplant Programs, Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
    Bone Marrow Transplant 33:381-8. 2004
  6. pmc Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
    Vaishali Sanchorawala
    Stem Cell Transplantation Program of the Section of Hematology Oncology, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 110:3561-3. 2007
  7. ncbi request reprint Light-chain (AL) amyloidosis: diagnosis and treatment
    Vaishali Sanchorawala
    Department of Medicine, Section of Hematology Oncology, Boston University Medical Center, Boston, Massachusetts, USA
    Clin J Am Soc Nephrol 1:1331-41. 2006
  8. ncbi request reprint An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis
    Vaishali Sanchorawala
    Section of Hematology Oncology in the Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
    Amyloid 14:261-9. 2007
  9. ncbi request reprint Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis
    V Sanchorawala
    Department of Medicine corrected Stem Cell Transplantation Program, Section of Hematology Oncology, Boston University School of Medicine corrected Boston, MA, USA
    Bone Marrow Transplant 40:557-62. 2007
  10. ncbi request reprint Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis
    Vaishali Sanchorawala
    Department of Medicine, Section of Hematology Oncology, Boston Medical Center, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
    Br J Haematol 117:886-9. 2002

Collaborators

Detail Information

Publications51

  1. pmc Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial
    Vaishali Sanchorawala
    Amyloid Treatment and Research Program, Section of Hematology and Oncology, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA
    Haematologica 98:789-92. 2013
    ..In conclusion, this combination is associated with significant myelosuppression leading to dose modifications and producing minor hematologic responses in AL amyloidosis. http://clinicaltrials.gov/ct2/show/NCT00679367...
  2. ncbi request reprint AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes
    V Sanchorawala
    Department of Medicine, Boston University Medical Center, Boston, MA, USA
    Am J Hematol 81:692-5. 2006
    ..However, high-dose melphalan and stem cell transplantation was the primary therapy in 5 patients, and each of these patients had prolonged survival, ranging from 36 to 102 months...
  3. ncbi request reprint Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis
    V Sanchorawala
    Department of Medicine, Section of Hematology Oncology, Boston Medical Center, Boston, MA 02118, USA
    Bone Marrow Transplant 36:597-600. 2005
    ....
  4. ncbi request reprint Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
    Vaishali Sanchorawala
    Department of Medicine, F 302, 732 Harrison Ave, Boston University Medical Center, MA 02118, USA
    Blood 109:492-6. 2007
    ..Findings from this trial indicate that lenalidomide can be effective in treating AL amyloidosis...
  5. ncbi request reprint High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial
    V Sanchorawala
    Hematology and Stem Cell Transplant Programs, Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
    Bone Marrow Transplant 33:381-8. 2004
    ....
  6. pmc Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
    Vaishali Sanchorawala
    Stem Cell Transplantation Program of the Section of Hematology Oncology, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 110:3561-3. 2007
    ..001). In conclusion, HDM/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR...
  7. ncbi request reprint Light-chain (AL) amyloidosis: diagnosis and treatment
    Vaishali Sanchorawala
    Department of Medicine, Section of Hematology Oncology, Boston University Medical Center, Boston, Massachusetts, USA
    Clin J Am Soc Nephrol 1:1331-41. 2006
    ..This review outlines approaches to diagnosis, assessment of disease severity, and treatment of AL amyloidosis...
  8. ncbi request reprint An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis
    Vaishali Sanchorawala
    Section of Hematology Oncology in the Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
    Amyloid 14:261-9. 2007
    ..This review outlines an overview of high-dose intravenous melphalan and stem cell transplantation in the treatment of AL amyloidosis. An algorithm of our recommendations for the treatment of AL amyloidosis is also outlined...
  9. ncbi request reprint Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis
    V Sanchorawala
    Department of Medicine corrected Stem Cell Transplantation Program, Section of Hematology Oncology, Boston University School of Medicine corrected Boston, MA, USA
    Bone Marrow Transplant 40:557-62. 2007
    ..The median survival for all patients enrolled on the trial has not yet been reached. Thus, tandem cycles of HDM/SCT can increase the proportion of patients who achieve an HCR...
  10. ncbi request reprint Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis
    Vaishali Sanchorawala
    Department of Medicine, Section of Hematology Oncology, Boston Medical Center, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
    Br J Haematol 117:886-9. 2002
    ..This regimen appeared to be effective in inducing haematological responses in patients who received total doses of melphalan > 300 mg...
  11. doi request reprint Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis
    Vaishali Sanchorawala
    Section of Hematology Oncology, Department of Medicine, Boston University School of Medicine, 820 Harrison Avenue, Boston, MA 02118, USA
    Clin Lymphoma Myeloma Leuk 10:469-72. 2010
    ..However, only selected patients with AL amyloidosis are eligible for HDM/SCT because of amyloid-associated organ dysfunction...
  12. pmc Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65
    David C Seldin
    Section of Hematology Oncology, Boston University Medical Center, 650 Albany St, Boston, MA 02118, USA
    Blood 108:3945-7. 2006
    ....
  13. doi request reprint Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment
    Andrew J Cowan
    Amyloid Treatment and Research Program, Boston University School of Medicine, Massachusetts, USA
    Biol Blood Marrow Transplant 18:1935-8. 2012
    ..Thus, our data indicate that although amyloid involvement of the bone marrow is common, it does not negatively affect stem cell mobilization or neutrophil and platelet engraftment after HDM-SCT...
  14. doi request reprint Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis
    Saulius Girnius
    Amyloid Treatment and Research Program, Boston University School of Medicine, Boston, MA 02118, USA
    Ann Hematol 89:579-84. 2010
    ..Hematologic relapses occurred in 60% of patients at a median of 1 year after HDM/SCT. In conclusion, HDM/SCT can prolong overall survival in patients with MM/AL who are eligible to receive it...
  15. ncbi request reprint Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
    David C Seldin
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
    Blood 104:1888-93. 2004
    ..Thus, treatment of AL amyloidosis patients with HDM/SCT produces measurable and sustained improvements in quality of life, particularly in those patients who achieve hematologic CR...
  16. ncbi request reprint High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study
    Martha Skinner
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Ann Intern Med 140:85-93. 2004
    ..AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective...
  17. ncbi request reprint High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease
    Liam F Casserly
    Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Kidney Int 63:1051-7. 2003
    ..The efficacy and tolerability of such treatment for patients with AL amyloidosis-associated ESRD are unknown...
  18. pmc Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature review
    Martin Tam
    Graduate Medical Sciences Division, Boston University School of Medicine, Boston, Massachusetts, USA
    Amyloid 16:103-7. 2009
    ..A literature review of spontaneous liver rupture in patients with amyloidosis is presented...
  19. ncbi request reprint Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis
    David C Seldin
    Boston University Medical Center, Boston Medical Center, MA, USA
    Clin Lymphoma 3:241-6. 2003
    ..No complete hematologic responses were seen, but 25% of patients had a significant reduction in Bence-Jones proteinuria. Thus, while thalidomide has activity in AL amyloidosis, it also has significant toxicity in this patient population...
  20. ncbi request reprint Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis
    Amit Fadia
    The Renal Section, Stem Cell Transplant Program of the Hematology Oncology Section, and Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
    Kidney Int 63:1868-73. 2003
    ..The incidence and outcome of ARF as a complication of such treatment is not known...
  21. pmc Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease
    Saulius Girnius
    Department of Medicine, Boston University School of Medicine, Boston University School of Public Health, Boston, MA, USA
    Haematologica 94:1029-32. 2009
    ..In conclusion, hepatic disease improves in almost 2/3 patients treated with high-dose intravenous melphalan and autologous stem cell transplantation who have a complete or partial hematologic response to treatment...
  22. ncbi request reprint Association of acquired von Willebrand syndrome with AL amyloidosis
    Cynthia A Kos
    Department of Medicine, Boston University Medical Center, Boston, Massachusetts, USA
    Am J Hematol 82:363-7. 2007
    ..AVWS should be considered in AL amyloidosis patients with hemorrhagic diatheses and normal clotting factor levels...
  23. pmc Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
    Maria Teresa Cibeira
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 118:4346-52. 2011
    ..9 years, respectively. Thus, treatment of selected AL patients with HDM/SCT resulted in a high organ response rate and long OS, even for those patients who did not achieve CR...
  24. pmc Kidney dysfunction during lenalidomide treatment for AL amyloidosis
    Richard Specter
    Renal Section, Boston University School of Medicine, Boston, MA, USA
    Nephrol Dial Transplant 26:881-6. 2011
    ..The objective of this study is to characterize alterations in kidney function among patients with AL amyloidosis undergoing treatment with lenalidomide...
  25. doi request reprint Myocardial infarction with "clean coronaries" caused by amyloid light-chain AL amyloidosis: a case report and literature review
    Stephanie B Tsai
    Amyloid Treatment and Research Program, Boston Medical Center, 820 Harrison Avenue, Boston, MA, USA
    Amyloid 18:160-4. 2011
    ..Contemporary testing should aim to detect both forms of cardiac amyloidosis, which may impact management and prognosis...
  26. pmc Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment
    David C Seldin
    Amyloidosis Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston Medical Center, K5, 72 East Concord Street, Boston, MA 02118, USA
    Heart Fail Clin 7:385-93. 2011
    ..Growing numbers of treatment options exist for these diseases, and timely diagnosis and institution of therapy is essential for preservation of cardiac function...
  27. ncbi request reprint An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis
    V Sanchorawala
    Stem Cell Transplant Program of the Section of Hematology and Oncology, Medical Center, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
    Bone Marrow Transplant 28:637-42. 2001
    ....
  28. pmc Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience
    Andrew J Cowan
    Amyloid Treatment and Research Program, Boston University School of Medicine, Boston, MA, USA
    Haematologica 98:141-6. 2013
    ..Although a rare manifestation of amyloidosis, staining for amyloid should be considered in patients undergoing gastrointestinal biopsy who have unexplained chronic gastrointestinal symptoms...
  29. doi request reprint Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review
    Benjamin Freeman
    Section of Hematology and Oncology, Boston University School of Medicine, Boston, MA, USA
    Amyloid 19:156-60. 2012
    ..A literature review of thrombembolic complications in patients with amyloidosis is presented...
  30. ncbi request reprint Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis
    John L Berk
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
    Chest 124:969-77. 2003
    ..We hypothesized that disruption of pleural function by amyloid deposits underlies persistent pleural effusions (PPEs) in patients with AL disease...
  31. ncbi request reprint Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis
    Harun Akar
    Amyloid Treatment and Research Program at Boston Medical Center, Boston University School of Medicine, Boston, MA, 02118, USA
    Amyloid 12:210-5. 2005
    ..After a histologic tissue diagnosis of amyloidosis, determining the type as AL amyloidosis relies on a panel of hematologic tests to determine light chain clonality and the exclusion other forms of amyloidosis...
  32. doi request reprint Macroglossia - not always AL amyloidosis
    Andrew J Cowan
    Department of Medicine, Amyloid Treatment and Research Program, Boston University School of Medicine, Boston Medical Center, Massachusetts, USA
    Amyloid 18:83-6. 2011
    ....
  33. pmc Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure
    Bimalangshu R Dey
    Massachusetts General Hospital, Boston, MA, USA
    Transplantation 90:905-11. 2010
    ..Autologous stem-cell transplantation (ASCT) has become a common therapy for AL amyloidosis, but there is an exceedingly high treatment-related mortality in patients with heart failure...
  34. ncbi request reprint Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease
    L M Dember
    Renal Section, EBRC 504, Boston University Medical Center, 650 Albany Street, Boston, MA 02118, USA
    Ann Intern Med 134:746-53. 2001
    ..The impact of this treatment on associated renal disease is not known...
  35. doi request reprint A solitary mediastinal mass due to localized AL amyloidosis: case report and review of the literature
    Shayna Sarosiek
    Department of Medicine, Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA
    Amyloid 20:127-30. 2013
    ..We describe a case of a man presenting with a mediastinal mass diagnosed as amyloidosis, confirmed by mass spectrometry to consist of lambda light chains. Here we review the literature and discuss treatment options for this rare entity...
  36. doi request reprint Localized amyloidosis of the breast: a case series
    Marjory Charlot
    Section of Hematology and Oncology, Department of Medicine, Boston Medical Center, MA, USA
    Amyloid 18:72-5. 2011
    ..Thus, other than excisional biopsy to exclude malignancy, no systemic therapy is indicated for this disorder...
  37. ncbi request reprint Diaphragm paralysis in primary systemic amyloidosis
    John L Berk
    The Pulmonary Center, Boston University School of Medicine, MA 02118, USA
    Amyloid 12:193-6. 2005
    ..Nocturnal non-invasive ventilation lowered arterial carbon dioxide levels and improved daytime dyspnea. This is the first case associating AL amyloid-induced neuropathy with diaphragm dysfunction...
  38. ncbi request reprint Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis
    B Oran
    Department of Medicine, Boston University Medical Center, Boston, MA, USA
    Bone Marrow Transplant 35:567-75. 2005
    ..Thus, in this patient population, organ function and host and hematopoietic factors influence engraftment after PBSC rescue...
  39. ncbi request reprint Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy
    E B Choufani
    Section of Hematology and Oncology, Department of Medicine, Boston Medical Center, Boston, MA, USA
    Blood 97:1885-7. 2001
    ..Thus, aggressive treatment of the underlying plasma cell dyscrasia in AL amyloidosis can lead to the amelioration of amyloid-related factor X deficiency...
  40. ncbi request reprint Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis
    R L Comenzo
    Department of Medicine, Stem Cell Transplant Program, Boston Medical Center and Boston University School of Medicine, Massachusetts 02118, USA
    Br J Haematol 104:553-9. 1999
    ..The 100 d mortality was 20%. In conclusion, no definitive differences were identified between the mobilization regimens and IDM was an active regimen in AL for selected patients...
  41. pmc Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a 'melphalan recall' reaction
    M Rosenzweig
    Stem Cell Transplant Program in the Section of Hematology Oncology, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA
    Bone Marrow Transplant 45:21-4. 2010
    ..We conclude that an unusual cytokine-mediated febrile reaction can occur in patients with AL amyloidosis exposed to a second cycle of high-dose melphalan, which we have termed a 'melphalan recall' reaction...
  42. ncbi request reprint Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation
    K Weichman
    Section of Hematology Oncology, Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
    Bone Marrow Transplant 38:339-43. 2006
    ..In our experience, HDM/SCT is a feasible and effective treatment approach for these disorders...
  43. ncbi request reprint Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis
    Eben I Lichtman
    Amyloidosis Center, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts
    Am J Hematol 89:706-8. 2014
    ..Am. J. Hematol. 89:706-708, 2014. © 2014 Wiley Periodicals, Inc. ..
  44. doi request reprint Amyloidomics comes of age
    David C Seldin
    Boston University School of Medicine, USA
    Blood 119:1795-6. 2012
    ..In this issue of Blood, Brambilla et al report a new methodology for accomplishing the key third step in this process...
  45. ncbi request reprint Cardiac amyloidosis: evolving approach to diagnosis and management
    Hans K Meier-Ewert
    Section of Cardiovascular Medicine and Amyloid Treatment and Research Program, Boston University School of Medicine, C 8, 88 East Newton Street, Boston, MA, 02118, USA
    Curr Treat Options Cardiovasc Med 13:528-42. 2011
    ..For familial amyloid derived from variant TTR, liver transplantation is the one validated treatment; however, small molecule therapeutic agents now in clinical trials appear capable of slowing or halting TTR amyloid deposition...
  46. ncbi request reprint A case of atypical light chain deposition disease--diagnosis and treatment
    David J Salant
    Renal Section, Department of Medicine, University Medical Center, Boston, MA, USA
    Clin J Am Soc Nephrol 2:858-67. 2007
  47. ncbi request reprint Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis
    G Akpek
    Section of Hematology and Oncology, Department of Medicine, Boston University Medical Center, Boston, MA, USA
    Bone Marrow Transplant 28:1105-9. 2001
    ....
  48. ncbi request reprint Spontaneous rupture of the spleen in AL amyloidosis
    B Oran
    Department of Medicine, Boston University Medical Center, Boston, Massachusetts 02118, USA
    Am J Hematol 74:131-5. 2003
    ..All four patients underwent splenectomy without significant postoperative complications. Splenic rupture in AL amyloidosis as a complication of aggressive treatment with HDM/SCT has not been reported previously...
  49. ncbi request reprint Azotemia associated with use of lenalidomide in plasma cell dyscrasias
    Eric D Batts
    University Hospitals Case Medical Center and Ireland Cancer Center and Case Comprehensive Cancer Center, Cleveland, OH, USA
    Leuk Lymphoma 49:1108-15. 2008
    ..We advise careful monitoring of renal function after initiation of lenalidomide in this setting...
  50. ncbi request reprint Adapting to AL amyloidosis
    David C Seldin
    Haematologica 91:1591-5. 2006
  51. ncbi request reprint Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004
    Morie A Gertz
    Dysproteinemia Clinic, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 79:319-28. 2005
    ..We report criteria that centers can now use to define organ involvement and uniform response criteria for reporting outcomes in patients with light-chain AL...